Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00792142 · ClinicalTrials.gov registry record · Phase 2
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00792142 is a Phase 2 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT00792142, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with thalidomide and dexamethasone may kill any cancer cells that remain after high-dose melphalan and stem cell transplant in patients with multiple myeloma. PURPOSE: This phase II trial is studying the side effects of giving bortezomib together with thalidomide and dexamethasone after melphalan and stem cell transplant and to see how well it works in treating patients with stage I-III multiple myeloma.
Interventions
- DRUG dexamethasone
- DRUG melphalan
- DRUG bortezomib
- GENETIC cytogenetic analysis
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2008-01-16 |
| Est. Completion | 2014-04-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00792142
The ClinicalTrials.gov registry entry for NCT00792142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which dexamethasone is the first listed.
NCT00792142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00792142 about?
NCT00792142 is a clinical study titled "Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma". RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with thalidomide and dexamethasone may kill any c...
What is the current status of trial NCT00792142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2008-01-16. Estimated completion is 2014-04-21.
What interventions are being tested in trial NCT00792142?
The interventions under investigation include: dexamethasone (DRUG), melphalan (DRUG), bortezomib (DRUG), cytogenetic analysis (GENETIC), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00792142?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.